Phio Pharmaceuticals
PHIO
1 hedge funds and large institutions have $2.98M invested in Phio Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
15% less capital invested
Capital invested by funds: $3.51M → $2.98M (-$529K)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$100K |
| 2 |
Jane Street
New York
|
-$56K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$28K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$25K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$5K |
PHIO Hedge Fund Activity: Q4 2014 in Review
1 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q4 2014, worth a combined $2.98M — down 15% from $3.51M a quarter earlier.
Fund positioning in PHIO was balanced in Q4 2014: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was Tang Capital Management, cutting an estimated $100K.
- 1 institutional investor held Phio Pharmaceuticals (PHIO) as of Q4 2014, unchanged from Q3 2014.
- Funds reported $2.98M of Phio Pharmaceuticals stock for Q4 2014, down 15% quarter-over-quarter.
- 0 funds opened new Phio Pharmaceuticals positions in Q4 2014 and 0 closed out.
- The largest Phio Pharmaceuticals seller in Q4 2014 was Tang Capital Management, an estimated $100K sold.
Based on aggregated 13F filings for Q4 2014.